Acrylamides / pharmacology Afatinib / pharmacology Aniline Compounds / pharmacology Animals Carcinoma, Non-Small-Cell Lung / drug therapy Cell Line, Tumor Drug Resistance, Neoplasm ErbB Receptors / genetics Female Gene Amplification Humans Lung Neoplasms / drug therapy Mice Neoplasm Transplantation Proto-Oncogene Proteins p21(ras) / genetics Pyrimidines / pharmacology Sequence Deletion

Journal

Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535

Informations de publication

Date de publication:
01 2019
Historique:
received: 02 06 2018
revised: 24 08 2018
accepted: 09 10 2018
pubmed: 17 10 2018
medline: 26 11 2019
entrez: 17 10 2018
Statut: ppublish

Résumé

The critical T790M mutation in

Identifiants

DOI: 10.1158/1535-7163.MCT-18-0591 PMID: 30322949
pubmed: 30322949
pii: 1535-7163.MCT-18-0591
doi: 10.1158/1535-7163.MCT-18-0591
doi:

Substances chimiques

Acrylamides 0
Aniline Compounds 0
KRAS protein, human 0
Pyrimidines 0
osimertinib 3C06JJ0Z2O
Afatinib 41UD74L59M
rociletinib 72AH61702G
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112-126

Informations de copyright

©2018 American Association for Cancer Research.

Auteurs

Kaori Nakatani (K)

Department of Healthcare and Regulatory Sciences, Showa University School of Pharmacy, Tokyo, Japan.

Toshimitsu Yamaoka (T)

Advanced Cancer Translational Research Institute (formerly, Institute of Molecular Oncology), Tokyo, Japan. yamaoka.t@med.showa-u.ac.jp.

Motoi Ohba (M)

Advanced Cancer Translational Research Institute (formerly, Institute of Molecular Oncology), Tokyo, Japan.

Ken-Ichi Fujita (KI)

Advanced Cancer Translational Research Institute (formerly, Institute of Molecular Oncology), Tokyo, Japan.

Satoru Arata (S)

Advanced Cancer Translational Research Institute (formerly, Institute of Molecular Oncology), Tokyo, Japan.
Center for Biotechnology, Showa University, Tokyo, Japan.

Sojiro Kusumoto (S)

Division of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

Iori Taki-Takemoto (I)

Department of Healthcare and Regulatory Sciences, Showa University School of Pharmacy, Tokyo, Japan.

Daisuke Kamei (D)

Department of Healthcare and Regulatory Sciences, Showa University School of Pharmacy, Tokyo, Japan.

Shinichi Iwai (S)

Department of Healthcare and Regulatory Sciences, Showa University School of Pharmacy, Tokyo, Japan.

Junji Tsurutani (J)

Advanced Cancer Translational Research Institute (formerly, Institute of Molecular Oncology), Tokyo, Japan.
ORCID: 0000-0002-6260-6943

Tohru Ohmori (T)

Advanced Cancer Translational Research Institute (formerly, Institute of Molecular Oncology), Tokyo, Japan.
Division of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés chimiques organiques › Acides carboxyliques › Acides acycliques › Acrylates › Acrylamides ›
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinazolines › Afatinib ›
questionsmedicales.fr › Composés chimiques organiques › Amines › Dérivés de l'aniline ›
questionsmedicales.fr › Eucaryotes › Animaux ›
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules ›
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale ›
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques ›
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteurs ErbB ›
questionsmedicales.fr › Phénomènes génétiques › Mutagenèse › Amplification de gène ›
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains ›
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon ›
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris ›
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale ›
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes p21(ras) ›
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines ›
questionsmedicales.fr › Phénomènes génétiques › Mutagenèse › Délétion de séquence ›